Effects of safflower yellow on angiotensin receptor II1 of kidney cells in diabetic nephropathy rats

doi:10.3969/j.issn.2095-4344.2016.18.014

Abstract

Abstract:

BACKGROUND: Safflower yellow is known to treat diabetic nephropathy, can protect kidney function, reduce lesions, delay or prevent the development of diabetic nephropathy.

OBJECTIVE: To further verify the effects of safflower yellow on the kidney in rats with diabetic nephropathy and the impact of safflower yellow on the expression of renal cell receptor of angiotensin II1.

METHODS: Thirty rats were equally and randomly divided into three groups: normal control group, model group and experimental group. In the experimental group and model group, rat models of diabetic nephropathy were established. At 1 week after model establishment, rats were daily intraperitoneally given safflower yellow injection 27.8 mg/kg, once a day. In the model and control groups, rats were daily intraperitoneally given an equal volume of saline. All rats were administered for 23 weeks. The kidney-related biochemical indicators and pathological changes in kidney tissue and the expression of angiotensin II1 type receptor on kidney tissue of rats were observed.

RESULTS AND CONCLUSION: (1) Hypertrophy index of experimental group and model group was significantly higher than that of control group (P < 0.05). (2) 24-hour proteinuria, glycosylated hemoglobin, total cholesterol, triglycerides, creatinine and urea nitrogen of model group were higher than that of control group (P < 0.05). 24-hour proteinuria, glycated hemoglobin, total cholesterol and urea nitrogen in experimental group were higher than that of control group (P < 0.05). 24-hour proteinuria, total cholesterol, triglycerides, creatinine and urea nitrogen in the experimental group were lower than that of model group (P < 0.05). (3) Glomerular hypertrophy, thickening of capillary basement membrane, cell proliferation, and mesangial widening were detected in the model group. Abnormal changes in the kidney structure were found in the control group. The extent of damage of kidney of histopathology in the experimental group was between the control group and the model group. (4) The expression level of angiotensin receptor II1 of experimental group and model group was higher than that of control group (P < 0.05). The expression level of angiotensin receptor II1 of experimental group was lower than that of model group (P < 0.05). These results indicated that safflower yellow has a protective effect on diabetic nephropathy; the mechanism of action may be associated with blocking kidney partial renin-angiotensin system.
中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

Key words: Diabetic Nephropathies, Renin-Angiotensin System, Carthamus Tinctorius, Tissue Engineering

Gao Yan, Yuan Lu-liang, Zhang Hai-song. Effects of safflower yellow on angiotensin receptor II1 of kidney cells in diabetic nephropathy rats [J]. Chinese Journal of Tissue Engineering Research, 2016, 20(18): 2677-2683.

Figures/Tables 5

References

[1] Hotta N, Kawamori R, Fukuda M, et al. Short Report: TreatmentLong-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy. Diabet Med. 2012;29 (12):1529-1533.

[2] 苏彦君,郝存勖,王青菊,等.姜黄素对实验性糖尿病大鼠肾脏蛋白激酶C移位活化的抑制作用[J].河北医药, 2010, 32(24): 3434-3436.

[3] Shepler B,Nash C,Smith C,et al.Update on Potential Drugs for the Treatment of Diabetic Kidney Disease. Clin Ther. 2012;34(6):1237-1246.

[4] Zhou X, Wang B, Zhu L, et al. A novel improved therapy strategy for diabetic nephropathy:Targeting AGEs. Organogenesis.2012;8(1):18-21.

[5] 丁瑞恒,廖蕴华. 黄芪对晚期糖基化终末产物作用下肾小球系膜细胞的影响[J].江苏中医药.2011,43(3):82-84.

[6] 余伍中,高国胜,翁光明.黄芪注射液对早期糖尿病肾病肾功能指标的影响[J].浙江临床医学.2012,14(12):1508- 1509.

[7] 施海涛,王雪峰,董春玲,等.冬虫夏草制剂治疗糖尿病肾病的作用机制研究进展[J].健康必读.2011,(9):332-332.

[8] 施海涛,杨庆春,王雪峰,等.冬虫夏草对延缓糖尿病肾病肾小球系膜细胞增殖的研究[J].中国现代医生.2011,49(22): 11-12.

[9] 张煜敏,杨丽萍,沈波.金水宝胶囊治疗糖尿病肾病的系统评价[J].现代中西医结合杂志.2012,21(23):2509-2512.

[10] 陈艳,吴晨光,王丽,等.α-硫辛酸对糖尿病大鼠肾脏聚 ADP-核糖多聚酶表达的影响[J].江苏医药，2011,37(6): 624-626.

[11] Yi X, Xu L, Hiller S, et al. Reduced expression of lipoic acid synthase accelerates diabetic nephropathy.J Am Soc Nephrol. 2012;23(1): 103-111.

[12] 李雪峰,李艳颖,贾文红,等.a-硫辛酸治疗43例Ⅲ期糖尿病肾病患者疗效分析[J].中国慢性病预防与控制, 2011, 19(5): 506-508.

[13] Hwang I,Lee J, Huh JY, et al. Catalase deficiency accelerates diabetic renal injury through peroxisomal dysfunction. Diabetes. 2012;61(3):728-738.

[14] Zhang Y, Peng F,Gao B,et al.High glucose-induced RhoA activation requires caveolae and PKCβ1-mediated ROS generation.Am J Physiol Renal Physiol.2012;302(1): F159-172.

[15] 王雅芸,徐家蓉,缪珩,等.白藜芦醇对糖尿病大鼠肾皮质氧化应激损伤的保护作用[J].中华糖尿病杂志，2012,4(4): 229-233.

[16] 田华生,宋丹玲.尿毒清颗粒治疗糖尿病肾病肾功能不全的疗效观察[J].临床内科杂志,2011,28(5):350-351.

[17] 李群苑,毛林浩.糖尿病肾病患者的临床分析[J].当代医学，2011,17(23):49-50.

[18] 刘会贞,刘雯,李金荣,等.RAS 双重阻断治疗糖尿病肾病患者的疗效[J].中国老年学杂志,2011,31(11):1964-1966

[19] Banki NF,Ver A,WagnerLJ,et al.Aldosterone Antagonists in Monotherapy Are Protective against Streptozotocin-Induced Diabetic Nephropathy in Rats.PLoS One. 2012;7 (6): e39938.

[20] 李世云,李勤,李黎,等.螺内酯对 2 型糖尿病肾病患者尿清蛋白的影响[J].中国全科医学,2011,14(33):3784- 3786.

[21] 刘小娟,杨藕罗,冯辉亮.厄贝沙坦联合螺内酯治疗糖尿病肾病微量蛋白尿的临床疗效观察[J].中国医药指南,2012, 10(2):25-26.

[22] 梁国瑞,刘俊霞.贝那普利和螺内酯联合治疗糖尿病肾病的临床研究[J].中国医药科.2012,2(2):99-99.

[23] 马东蔚,王秋月. Rho/Rho激酶信号通路与糖尿病肾病[J].国际内分泌代谢杂志,2011,31(3):193-195.

[24] 王丹,施辉范,亚平,等.螺内酯对 ROCK1 在单肾切除糖尿病大鼠肾组织中表达及活性的影响[J].中华肾脏病杂志,2012,28(7): 512-517.

[25] 王洋.TSC-mTOR 信号通路在糖尿病及糖尿病肾病发病机制中的作用[J].广西医学,2010,32(3):354-358

[26] Zhang S,Cai G,Fu B,et al.SIRT1 is required for the effects of rapamycin on high glucose-inducing mesangial cells senescence. Mech Ageing Dev. 2012;133 (6): 387-400.

[27] 刘磊,常保超,郝丽.霉酚酸酯对糖尿病大鼠肾组织中TGF-β1 与 OPN 表达的影响[J].中华全科医学, 2011, 9(5):676-677.

[28] YU WM,WANG H,REN XJ,et al. Experimental study of leflunomide on renal Protective effect and on inflammatory response of streptozotocin induced diabetic rats.Nephrology (Carlton).2012;17(4): 380-389.

[29] 李洁,张乾坤,金烈.糖尿病肾病大鼠足细胞的影响[J].浙江实用医学.2012,17(1):10-12.

[30] 宋纯东,薛黎明.雷公藤多甙对早期糖尿病肾病大鼠肾组织 TGF-β1表达的影响[J].中国中医药科技,2011, 18(2): 125-126.

[31] 辛小龙,王静.不同剂量雷公藤多甙治疗糖尿病肾病的短期疗效差异[J]. 现代中西医结合杂志.2011,20(30): 3815-3816.

[32] 中国医师协会内分泌代谢科医师分会.2 型糖尿病合并慢性肾脏病患者口服降糖药用药原则中国专家共识[J].中国糖尿病杂志,2013,21(10):865-870.

[33] 叶俊鹏,黄培良,赖瑞平. 门诊常用降脂药物的用药分析[J].现代医院2013,13(12):65-67.

[34] 金秀名. 血液透析与腹膜透析治疗糖尿病肾病的疗效观察[J].中国实用医药,2014,9(1):118-119.

[35] 陆翰澜,陈瑜,傅尚希,等. 亲属活体肾移植后供者安全性评价[J].中国组织工程研究,2013,17(44):7681-7686.

[36] 李建国,胡齐鸣,张宝霞,等.益气养阴收敛固涩方治疗气阴两虚型糖尿病肾病30例临床观察[J].实用中西医结合临床,2014,14(3):77-78

[37] 郭彦军.益肾化瘀方治疗糖尿病肾病疗效观察[J].陕西中医,2013,34(8):954-955.

[38] 蒋丙义. 血府逐瘀汤治疗43例糖尿病肾病临床效果观察[J].基础医学论坛,2014,18(14):1854-1855.

[39] 万秋,刘秀明,杨文婷.红花黄色素研究概述[J].生命的化学, 2013,33(2):54-58．

[40] 刘俐,魏云,卜振军,等.红花黄色素对犬心肌缺血及血流动力学的影响[J].中国医药科学,2013,24:26-28．

[41] 郭雪婷,杨晓君,王颖．复合红花黄色素抗凝血作用研究[J].新疆农业科学,2012,49(9):1759-1763．

[42] 苏慧,刘萍,温薇,等.红花黄色素冻干粉针对大鼠体内体外血栓形成的影响[J].中医药信息,2012,29(6):29-30．

[43] 韩进庭．红花黄色素在髋关节置换术后预防下肢静脉血栓中的应用[J].中国实用医药,2013,8(26):192-193．

[44] 薛新宏,赵小明,彭延波,等．雌激素联合依达拉奉对大鼠脑缺血再灌注的神经保护作用[J].河北医药,2013,35(3): 325-327．

[45] 王晓丽,王毅,张赛,等.红花黄色素对大鼠脑缺血再灌注损伤的保护作用[J].中华实用诊断与治疗杂志,2014,28(1): 12-14．

[46] Zhang N,Xing MY,Wang YY,et al．Hydroxysaf ower yellow A improves learning and memory in a rat model of vascular dementia by increasing VEGF and NR1 in the hippocampus.Neurosci Bull.2014;30(3):417-424．

[47] 胡波,裴昌录,李小川．注射用红花黄色素对股骨折患者炎症因子影响探讨[J].辽宁中医药大学学报,2013,15(8): 201-203．

[48] 白雪梅,李向东,宋洁,等. 红花黄色素对早期糖尿病肾病患者hs-CRP、IL-8的影响[J].中国中西医结合肾病杂志, 2012,13(8):698-700．

[49] 郭登洲,王月华,边东,等．红花黄色素对糖尿病肾病大鼠血管紧张素系统的影响[J].中成药,2009,31(12): 1832-1836．